Biocon to start selling breast cancer drug in India in February

Biocon  said its generic version of Roche's Herceptin breast 

cancer treatment would be available to patients in India from 


the first week of February. Bangalore-based Biocon jointly 

developed biosimilar trastuzumab, which received the Indian 


drug regulator's marketing approval in November, with US-

based Mylan Inc. About 150,000 people are diagnosed with 


breast cancer every year in India, of which 25 percent are 

eligible for treatment with trastuzumab, Biocon said. Roche 


decided not to pursue a patent application for its breast 

cancer drug Herceptin in India, paving the way for generic 


drugmakers to produce cheaper copies, known as 

biosimilars because they are not identical to the original 


drug. 

ps- this is only for information, always consult you physician before having any particular food/ medication/exercise/other remedies.

ps- those interested in recipes are free to view my blog-

http://gseasyrecipes.blogspot.com/

for info about knee replacement, you can view my blog-

http://Knee replacement-stick club.blogspot.com/

for crochet designs

http://My Crochet Creations.blogspot.com